MX2020007947A - Inhibidores de erbb/btk. - Google Patents
Inhibidores de erbb/btk.Info
- Publication number
- MX2020007947A MX2020007947A MX2020007947A MX2020007947A MX2020007947A MX 2020007947 A MX2020007947 A MX 2020007947A MX 2020007947 A MX2020007947 A MX 2020007947A MX 2020007947 A MX2020007947 A MX 2020007947A MX 2020007947 A MX2020007947 A MX 2020007947A
- Authority
- MX
- Mexico
- Prior art keywords
- erbbs
- erbb
- btk
- btk inhibitors
- mutant forms
- Prior art date
Links
- 229940124291 BTK inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Se revelan compuestos que inhiben ErbB (por ejemplo EGFR o Her 2), especialmente las formas mutantes de ErbB, y BTK, sales farmacéuticamente aceptables, hidratos, solvatos o estereoisómeros de los mismos, y composiciones farmacéuticas que comprenden los compuestos. El compuesto y la composición farmacéutica puede tratar de manera efectiva las enfermedades asociadas con ErbB (especialmente las formas mutantes de ErbBs) o BTK, incluido el cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018074791 | 2018-01-31 | ||
| CN2018118569 | 2018-11-30 | ||
| PCT/CN2019/073355 WO2019149164A1 (en) | 2018-01-31 | 2019-01-28 | Erbb/btk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007947A true MX2020007947A (es) | 2021-02-09 |
Family
ID=67478612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007947A MX2020007947A (es) | 2018-01-31 | 2019-01-28 | Inhibidores de erbb/btk. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11007198B2 (es) |
| EP (2) | EP3746424B1 (es) |
| JP (2) | JP7427597B2 (es) |
| KR (1) | KR20210013544A (es) |
| CN (3) | CN111747934A (es) |
| AU (2) | AU2019215538B2 (es) |
| BR (1) | BR112020015726A2 (es) |
| CA (1) | CA3086616A1 (es) |
| DK (1) | DK3746424T3 (es) |
| MX (1) | MX2020007947A (es) |
| PT (1) | PT3746424T (es) |
| RU (2) | RU2764069C1 (es) |
| TW (1) | TWI798334B (es) |
| WO (1) | WO2019149164A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI798334B (zh) * | 2018-01-31 | 2023-04-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｅｒｂｂ／ｂｔｋ抑制劑 |
| US11896597B2 (en) * | 2018-01-31 | 2024-02-13 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | ErbB/BTK inhibitors |
| CN115838369A (zh) | 2019-03-19 | 2023-03-24 | 株式会社沃若诺伊 | 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物 |
| CN113179640A (zh) * | 2019-11-26 | 2021-07-27 | 上海翰森生物医药科技有限公司 | 含氮多环类衍生物抑制剂、其制备方法和应用 |
| CN111057021B (zh) * | 2019-12-11 | 2023-05-23 | 中国药科大学 | 均三嗪类化合物及其制备方法和用途 |
| CN115279373A (zh) * | 2020-01-07 | 2022-11-01 | 达纳-法伯癌症研究所股份有限公司 | Egfr/her2的氰基嘧啶抑制剂 |
| CN111470998B (zh) * | 2020-06-28 | 2020-09-25 | 上海皓元生物医药科技有限公司 | 用于合成喜树碱衍生物的中间体及其制备方法和用途 |
| CN112409281B (zh) * | 2020-08-20 | 2022-11-18 | 上海大学 | (e)-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的合成方法 |
| CN112679446A (zh) * | 2020-10-26 | 2021-04-20 | 都创(上海)医药科技有限公司 | 一种合成反式-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的方法 |
| CN116670127A (zh) * | 2021-03-30 | 2023-08-29 | 贝达药业股份有限公司 | Egfr抑制剂及其组合物和用途 |
| KR20240042640A (ko) * | 2021-08-02 | 2024-04-02 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | Erbb 및 btk 억제제의 신규한 약제학적 염 및 다형체 형태 |
| CN115181093B (zh) * | 2022-08-01 | 2023-04-25 | 重庆医科大学 | Sunvozertinib中间体的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200538097A (en) * | 2004-02-27 | 2005-12-01 | Eisai Co Ltd | Novel pyridine derivative and pyrimidine derivative |
| KR20110025224A (ko) * | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| RS55704B1 (sr) * | 2012-01-17 | 2017-07-31 | Astellas Pharma Inc | Jedinjenje pirazin karboksamida |
| JP6317320B2 (ja) * | 2012-03-15 | 2018-04-25 | セルジーン シーエーアール エルエルシー | 上皮成長因子受容体キナーゼ阻害剤の塩 |
| CN104854101B (zh) | 2012-11-06 | 2018-05-01 | 上海复尚慧创医药研究有限公司 | Alk激酶抑制剂 |
| CN105377835B (zh) * | 2013-07-11 | 2018-08-17 | 贝达药业股份有限公司 | 酪氨酸蛋白激酶调节剂及其应用方法 |
| US9783524B2 (en) * | 2013-07-11 | 2017-10-10 | Betta Pharmaceuticals Co., Ltd. | Protein tyrosine kinase modulators and methods of use |
| EP3033079B1 (en) | 2013-08-12 | 2018-10-31 | Pharmacyclics LLC | Methods for the treatment of her2 amplified cancer |
| CN105384694B (zh) * | 2014-08-22 | 2020-09-04 | 四川海思科制药有限公司 | 一种取代的氨基嘧啶衍生物及其制备方法和药物用途 |
| CN106883213B (zh) * | 2015-12-15 | 2021-04-20 | 合肥中科普瑞昇生物医药科技有限公司 | 一种egfr和alk激酶的双重抑制剂 |
| CN106905245B (zh) * | 2015-12-23 | 2021-06-25 | 正大天晴药业集团股份有限公司 | 2,4-二取代的嘧啶类化合物 |
| CN106928150B (zh) * | 2015-12-31 | 2020-07-31 | 恩瑞生物医药科技（上海）有限公司 | 丙烯酰胺苯胺衍生物及其药学上的应用 |
| CN106083736A (zh) * | 2016-06-21 | 2016-11-09 | 郑州泰基鸿诺医药股份有限公司 | 一种嘧啶类化合物、egfr抑制剂及其应用 |
| TWI798334B (zh) * | 2018-01-31 | 2023-04-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｅｒｂｂ／ｂｔｋ抑制劑 |
| KR20190108079A (ko) * | 2018-03-13 | 2019-09-23 | 보로노이바이오 주식회사 | 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
-
2019
- 2019-01-17 TW TW108101860A patent/TWI798334B/zh active
- 2019-01-28 CA CA3086616A patent/CA3086616A1/en active Pending
- 2019-01-28 DK DK19748259.9T patent/DK3746424T3/da active
- 2019-01-28 PT PT197482599T patent/PT3746424T/pt unknown
- 2019-01-28 MX MX2020007947A patent/MX2020007947A/es unknown
- 2019-01-28 RU RU2020127393A patent/RU2764069C1/ru active
- 2019-01-28 EP EP19748259.9A patent/EP3746424B1/en active Active
- 2019-01-28 CN CN202010659802.9A patent/CN111747934A/zh active Pending
- 2019-01-28 WO PCT/CN2019/073355 patent/WO2019149164A1/en unknown
- 2019-01-28 JP JP2020541535A patent/JP7427597B2/ja active Active
- 2019-01-28 BR BR112020015726-0A patent/BR112020015726A2/pt unknown
- 2019-01-28 RU RU2021139070A patent/RU2021139070A/ru unknown
- 2019-01-28 EP EP24161138.3A patent/EP4356975A2/en active Pending
- 2019-01-28 CN CN201980006427.3A patent/CN111587244A/zh active Pending
- 2019-01-28 AU AU2019215538A patent/AU2019215538B2/en active Active
- 2019-01-28 KR KR1020207025029A patent/KR20210013544A/ko not_active Application Discontinuation
- 2019-01-28 CN CN202010660882.XA patent/CN111909131B/zh active Active
-
2020
- 2020-06-24 US US16/910,208 patent/US11007198B2/en active Active
-
2021
- 2021-04-07 US US17/224,121 patent/US11504375B2/en active Active
-
2023
- 2023-04-06 AU AU2023202151A patent/AU2023202151A1/en active Pending
- 2023-10-19 JP JP2023180451A patent/JP2024010038A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11504375B2 (en) | 2022-11-22 |
| US20200316079A1 (en) | 2020-10-08 |
| JP2021512087A (ja) | 2021-05-13 |
| PT3746424T (pt) | 2024-03-21 |
| CN111587244A (zh) | 2020-08-25 |
| EP4356975A2 (en) | 2024-04-24 |
| CN111909131A (zh) | 2020-11-10 |
| KR20210013544A (ko) | 2021-02-04 |
| RU2764069C1 (ru) | 2022-01-13 |
| JP7427597B2 (ja) | 2024-02-05 |
| US11007198B2 (en) | 2021-05-18 |
| RU2021139070A (ru) | 2022-01-26 |
| EP3746424A4 (en) | 2021-08-25 |
| CN111909131B (zh) | 2022-02-15 |
| AU2019215538A1 (en) | 2020-07-09 |
| AU2019215538B2 (en) | 2023-02-02 |
| US20210252005A1 (en) | 2021-08-19 |
| EP3746424B1 (en) | 2024-03-06 |
| BR112020015726A2 (pt) | 2020-12-08 |
| CA3086616A1 (en) | 2019-08-08 |
| JP2024010038A (ja) | 2024-01-23 |
| AU2023202151A1 (en) | 2023-05-04 |
| TWI798334B (zh) | 2023-04-11 |
| DK3746424T3 (da) | 2024-03-25 |
| WO2019149164A1 (en) | 2019-08-08 |
| CN111747934A (zh) | 2020-10-09 |
| TW201940472A (zh) | 2019-10-16 |
| EP3746424A1 (en) | 2020-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| MX2022006986A (es) | Inhibidores de kras g12c. | |
| MX2023008954A (es) | Inhibidores de los receptores erbb. | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| MD3606909T2 (ro) | Sare de sodiu a N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-izopropil-1H-pirazol-3-sulfonamidei | |
| MX2023008031A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| GEP20084439B (en) | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| MX2021002805A (es) | Terapias de combinacion. | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| MX2020011089A (es) | Compuestos antiproliferacion y usos de los mismos. | |
| MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| MX2021012105A (es) | Compuestos de pirrol. | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
| PH12019502652A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
| MX2021009717A (es) | Sulfonamidas biciclicas. | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2021014458A (es) | Compuestos triciclicos. |